Tag: market

Posted on

Asthma Therapeutics – Pipeline Assessment and Market Forecasts to 2018 – NEWS.GNOM.ES

Asthma Therapeutics – Pipeline Assessment and Market Forecasts to 2018
NEWS.GNOM.ES
ES/ — Reportlinker.com announces that a new market research report is available in its catalogue: GlobalData, the industry analysis specialist, has released its new report, “Asthma Therapeutics – Pipeline Assessment and Market Forecasts to 2018?. …
Asthma Therapeutics – Pipeline Assessment and Market Forecasts to 2018MarketWatch (press release)
Asthma Therapeutics – Pipeline Assessment and Market Forecasts to 2018Virtual Press Office (press release)

all 56 news articles »

View full post on asthma – Google News

Posted on

Research and Markets: the Asthma, COPD & Allergic Rhinitis Market Outlook to … – Business Wire (press release)

Research and Markets: the Asthma, COPD & Allergic Rhinitis Market Outlook to …
Business Wire (press release)
The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment. Of respiratory indications, asthma represents the main area of R&D interest for pharmaceutical …

and more »

View full post on asthma – Google News

Posted on

Reportlinker Adds The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016 – Centre Daily Times

Reportlinker Adds The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
Centre Daily Times
The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment. Of respiratory indications, asthma represents the main area of R&D interest for pharmaceutical …

and more »

View full post on asthma – Google News

Posted on

Reportlinker Adds The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016 – SYS-CON Media (press release)

Reportlinker Adds The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
SYS-CON Media (press release)
The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment. Of respiratory indications, asthma represents the main area of R&D interest for pharmaceutical …

and more »

View full post on asthma – Google News

Posted on

Clinical trials start for ABI’s breath asthma check rapid assay – Stock Market Wire

Clinical trials start for ABI's breath asthma check rapid assay
Stock Market Wire
StockMarketWire.com – Clinical trials for Akers Biosciences' breath asthma check rapid assay have begun in Clearwater, Florida. The trials have been designed to provide the clinical information to be included in a submission for regulatory approvals …
18 APRIL 2011 Akers Biosciences* AKR (FTSE AIM All Share) 4p BUY (TP-10p)AngelNews (press release) (subscription)

all 3 news articles »

View full post on asthma – Google News

Posted on

Skyepharma banking on European approval for Flutiform – Stock Market Wire

Skyepharma banking on European approval for Flutiform
Stock Market Wire
The group said it was counting on European approval of asthma treatment Flutiform and launch in the second half of 2011. Revenue was up 4% to £58.1m from £55.9m, in line with management expectations. The rise was primarily due to a substantial increase …
SkyePharma Moves To 2010 Pretax Profit, Sees Cash OutflowsWall Street Journal
STOCKS NEWS UK-SkyePharma up on results Flutiform optimismLondon South East
Skyepharma turns in annual profitShareCast

all 6 news articles »

View full post on asthma – Google News

Posted on

FDA Approves New Inhaler HFA Formulation for Asthma – Canada Drugs Online News – Market Press Release (press release)

FDA Approves New Inhaler HFA Formulation for Asthma – Canada Drugs Online News
Market Press Release (press release)
ProAir HFA provides you a fast relief when experiencing asthma, exercise-induced bronchospasm (EIB) and chronic obstructive pulmonary disease (COPD). It contains albuterol and is prescribed to patients not younger than 4 years of age. …

View full post on asthma – Google News